Provention Bio's $2.9B Acquisition - A Strategic Fit For Sanofi

  • Sanofi SA SNY has agreed to acquire Provention Bio Inc PRVB for $25.00 per share in cash, representing an equity value of approximately $2.9 billion.
  • The transaction adds a type 1 diabetes therapy to Sanofi's core asset portfolio in General Medicines, and further drives its strategic shift toward products with a differentiated profile. 
  • In November 2022, the FDA approved Tzield (teplizumab-mzwv) to delay the onset of stage 3 type 1 diabetes in adults and pediatric patients eight years and older with stage 2 type 1 diabetes
  • The purchase builds on an existing co-promotion agreement with Provention Bio, already delivering Tzield to patients needing this immune-mediated therapy.
  • Tzield is also in late-stage clinical development for pediatric and adolescent patients newly diagnosed with clinical T1D (Stage 3). 
  • A Phase 3 trial, PROTECT, is underway, and top-line results are expected in the second half of 2023. 
  • Additional opportunities for TZIELD include re-dosing and formulations and new therapeutic indications.
  • Sanofi currently expects to complete the acquisition in the second quarter of 2023.
  • Price Action: PRVB shares are up 257.90% at $23.98 on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechLarge CapM&ANewsHealth CareSmall CapMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!